Recent financial activities and corporate restructurings reflect biotech’s dynamic investment climate. Vor Bio rebounded with a $175 million private equity infusion supporting its autoimmune pipeline after significant layoffs. 4D Molecular Therapeutics narrowed operations with 25% workforce reductions to accelerate pivotal phase 3 gene therapy trials in ophthalmology. Concentra Biosciences extended its spree of acquisitions by securing IGM Biosciences, continuing its consolidation of struggling biotech firms. New venture funds such as Catalio Capital’s $400 million Nexus Fund IV and Japan-focused AN Venture Partners’ $200 million initial close underscore growing capital flows aimed at innovation and expansion.